Skip to main content
Signal8
Launch Terminal

Savara Inc (SVRA)

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Savara Inc. logo

Savara Inc.

NASDAQ:SVRAHealthcare
-2.63%$4.82
AH$4.87+1.04%vs close
Mkt Cap$990.32M
Float143.33M
O/S205.46M
Vol
$ Vol
RVOL
Inst Own-
SI20.1%
Earnings
Dilution
Savara Inc. logoNASDAQ:SVRA$4.82-2.63%
FormDescription
4
Statement of Changes in Beneficial Ownership
S-8
SEC Filing
1
10-Q
Quarterly Report
6
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
144
Notice of Proposed Sale of Securities
8-K
5.02,5.03,5.07,9.01
10-Q
Quarterly Report
ARS
SEC Filing
DEFA14A
Additional Proxy Materials
DEF 14A
Definitive Proxy Statement
PRE 14A
Preliminary Proxy Statement
4
Statement of Changes in Beneficial Ownership
8-K
1.01,9.01
10-K
Annual Report
13G/A
Beneficial Ownership Report (Amended)
4
Statement of Changes in Beneficial Ownership
13G/A
Beneficial Ownership Report (Amended)
13G/A
Beneficial Ownership Report (Amended)
13G/A
Beneficial Ownership Report (Amended)
13G/A
Beneficial Ownership Report (Amended)
8-K
1.01,2.03
13G
Beneficial Ownership Report
8-K
7.01,9.01
4
Statement of Changes in Beneficial Ownership

1-25 of 1,339

…